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eft Main Percutaneous
oronary Intervention
rossing the Threshold
ime for a Guidelines Revision!*
effrey W. Moses, MD, Martin B. Leon, MD,
regg W. Stone, MD
ew York, New York
urgery with coronary artery bypass grafting (CABG) has
een the standard of care for obstructive left main coronary
isease for more than 3 decades. The benefits of CABG as
xemplified in the Coronary Artery Surgery Study coupled
ith the dismal early outcomes of percutaneously treating
eft main disease with balloon angioplasty created a “forbid-
en zone” for interventionalists (1,2).
See page 1500
Over the last several years, this “terra incognita” has been
nvaded by interventionalists on a widespread scale. A
urrent literature search revealed more than 200 peer-
eviewed citations in the past 30 months (including more
han half a dozen editorials in major cardiology journals)
edicated to the subject of left main percutaneous coronary
ntervention (PCI). Much of these data stem from a
enewed enthusiasm for left main intervention with drug-
luting stents (DES), reinforced by meta-analyses of ran-
omized trials indicating equivalent 5- to 10-year rates of
ortality and myocardial infarction in patients undergoing
ultivessel PCI compared with CABG (3,4). Favorable
ecent studies of left main DES include single-center
egistries (5), propensity-matched cohorts compared with
ABG (6), meta-analyses of multicenter registries (7,8),
nd most importantly, the 705-patient left main subset
nalysis of the SYNTAX (Synergy Between Percutaneous
oronary Intervention with Taxus and Cardiac Surgery)
andomized trial (9). The diversity and richness of these
ata sets are themselves a clear indication that left main PCI
s now in widespread clinical practice across the globe.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From Columbia University Medical Center/New York Presbyterian Hospital andt
he Cardiovascular Research Foundation, New York, New York. Dr. Moses has
erved as a speaker for Cordis and Abbott (modest).In this context, LE MANS (Unprotected Left Main
tenting Versus Bypass Surgery) Registry collaborators
hould be congratulated. In this issue of the Journal, they
eport an 11-year collaborative effort that began in 1997 in
single country to evaluate the outcomes of left main PCI
10). In the course of this investigation, they also conducted
previously published modest-sized successful randomized
rial comparing bare-metal stenting with CABG (11). The
ighly selected 252 patients in the current report represent
heterogeneous cohort, given the evolution of technique
nd technology during the course of the study inclusion time
pan. Nonetheless, certain conclusions can be drawn from
heir observations: 1) left main stenting in skilled hands can
e performed with low morbidity and mortality with no late
catch-up”; 2) DES have improved clinical outcomes com-
ared with bare-metal stents, principally by substantially
educing the need for repeat revascularization; 3) the rates of
arly, late, and very late thrombosis are low despite the
imited use of dual antiplatelet therapy after 2 years with
oth stent types; and 4) long-term survival after left main
tenting is excellent in those patients with left main disease
ithout concomitant 3-vessel disease.
The power of these observations are somewhat limited by
lack of randomization against surgery (or even a matched
ontrol group from the 1,700 CABG surgeries performed in
hese centers during this period), the small numbers of
atients followed beyond 4 years, and the even smaller
umbers treated with DES with late follow-up. Nonethe-
ess, there is striking concordance when these findings are
ompared with both recent large observational registries and
merging data from the left main subset of the SYNTAX
rial, in which paclitaxel-eluting stents compared with
ABG in patients with left main disease and either low- or
oderate-risk coronary artery anatomic complexity resulted
n comparable or lower rates of composite major adverse
ardiovascular events.
Thus, in 2009, the weight of evidence supports the
osition that: 1) left main PCI with DES of the ostium or
haft can be performed with very low morbidity and
ortality and with very low rates of repeat revascularization;
) stenosis of the distal left main can be effectively treated
ith a single “crossover” stent in the majority of cases and
as become the current preferred strategy; 3) stent throm-
osis of the left main segment is infrequent; and 4) PCI
ith DES will result in noninferior outcomes to CABG in
any patients with unprotected left main disease, although
elected patients with very complex and/or triple-vessel
isease still benefit from a primary surgical approach.
Numerous technical issues remain that need to be ad-
ressed in future clinical studies. Many would dispute the
E MANS group predilection for direct stenting. Many
xperienced left main treatment aficionados strongly favor
ggressive lesion preparation and/or intravascular ultra-
ound guidance. The threshold for stenting both limbs of
he distal left main bifurcation and the optimal bifurcation
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October 13, 2009:1512–4 Left Main PCIechnique vary considerably among operators (12). And
astly, special consideration must be given to patients in
hom long-term dual antiplatelet therapy may be problem-
tic because of compliance issues, bleeding diatheses, or
oncomitant use of vitamin K antagonists.
Based upon the mounting evidence, there can be little
ispute at this juncture that PCI can be offered as a safe
lternative to CABG for a significant number of patients
ith left main disease, particularly nondiabetics without
xtensive concomitant coronary artery disease. Left main
CI no longer needs to be confined to those patients who
damantly refuse or who are at unacceptably high risk for
ABG. As such, there is now sufficient clinical trial data to
ustify a relaxation of the American College of Cardiology/
merican Heart Association guidelines, such that left main
CI is no longer a Class III indication.
From a broader perspective, left main disease should be
iewed as an extreme case of chronic coronary artery disease
ith a particularly large area of myocardium at risk in which
evascularization is the preferred initial treatment strategy.
he concept of appropriately risk stratifying patients is vital
o the question of which patients with chronic coronary
rtery disease benefit from revascularization in general and
y PCI in particular. Recent data from the COURAGE
Clinical Outcomes Utilizing Revascularization and Ag-
ressive Drug Evaluation) trial, including the nuclear sub-
tudy and analysis of patients with silent ischemia, indicate
hat in patients with an important ischemic burden, PCI is
uperior in reducing ischemia and in improving outcomes
ompared with medical therapy alone (13,14). This position
s also supported by the recently published JSAP (Japanese
table Angina Pectoris) and BARI (Bypass Angioplasty
evascularization Investigation) 2-dimensional randomized
ontrol trials, indicating superiority of revascularization
ersus medical therapy in patients with either documented
schemia or a large amount of myocardium at risk (15,16).
uch observations should be placed in context with the
YNTAX trial, in which PCI with DES was either superior
r equivalent to CABG as a revascularization strategy in
atients with isolated left main disease or accompanying
ingle- or double-vessel disease (9). Only in the most
omplex patients with left main and associated 3-vessel
isease was CABG a superior revascularization choice.
hus, in circumstances of significant myocardium at risk
including the extreme case of left main disease), PCI
mproves clinical outcomes and provides a preferred therapy
lternative, even in patients with so-called “stable” coronary
rtery disease.
Undoubtedly, there is sufficient equipoise to justify a
efinitive multicenter, prospective, randomized, controlled
rial comparing DES with CABG to more clearly identify
he optimal revascularization pathways for individual pa-
ients with unprotected left main disease. Such a trial must
ave sufficient power to determine important differences in
ritical clinical end points such as death, myocardial infarc-
ion, and stroke, and also must be stratified to examinemportant anatomic, clinical, technique-related, and isch-
mic variables. However, the results from such a definitive
tudy are many years away, and in the interim, practicing
hysicians must make clinical decisions on the basis of the
est available evidence. The long-term LE MANS data
dds to the growing literature indicating that in many
atients, left main stenting can be offered as a safe and
ffective alternative to surgery. However, because quality
ssurance indicators are often “guidelines driven,” until there
s a change in the formal guidelines to more accurately
eflect the consensus shift in physician practice, the ap-
roach to left main revascularization will remain suspended
n the past, reflecting the conundrum of infrequently revised
uidelines and appropriateness criteria based on outdated
iterature (17). The rapid advancement of medical technol-
gy combined with the telescoping and globalization of
vidence-based medicine requires that critical practice
uidelines be continuously updated to provide our patients
ith the safest, most effective, and least invasive therapies in
timely fashion.
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olumbia University Medical Center and Cardiovascular Research
oundation, 161 Fort Washington Avenue, New York, New York
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